Compound News and Research

RSS

Bristol-Myers Squibb, ASLAN partner to develop BMS-777607 for solid tumors

ASLAN Pharmaceuticals Pte Ltd, a pharmaceutical company headquartered in Singapore, and Bristol-Myers Squibb Company today announced an innovative strategic partnership allowing for the rapid development of BMS-777607, Bristol-Myers Squibb's investigational small molecule inhibitor of the MET receptor tyrosine kinase for treatment of solid tumors.

4 Nov 2011

The brain and the heart may not be so different after all

What do heart disease and dementia have in common? Perhaps more than meets the eye, according to researchers at the University of Rochester Medical Center.

3 Nov 2011

Exendin-4 drug could prevent later development of diabetes in children

Pediatric researchers who tested newborn animals with an existing human drug used in adults with diabetes report that this drug, when given very early in life, prevents diabetes from developing in adult animals. If this finding can be repeated in humans, it may become a way to prevent at-risk infants from developing type 2 diabetes.

3 Nov 2011

Researchers use diabetes drug to permanently reprogram insulin-producing cells

3 Nov 2011

IP-K and Sanofi form new HBV research collaboration

One of the most common and serious infectious diseases, Hepatitis B, is to be targeted in a new collaborative venture between the internationally-renowned translational research institute, Institut Pasteur Korea (IP-K), and the Korean arm of the leading global healthcare company, Sanofi-Aventis Korea. The goal is to develop and validate a high throughput assay to screen IP-K's chemical libraries for novel compounds that can be developed as new drugs.

3 Nov 2011

Resveratrol holds key to reducing obesity and associated risks: Study

A new study shows that when taken regularly a natural compound known as resveratrol, found in red wine and grapes, mulberries and peanuts, can offer similar benefits to low-calorie diets and endurance training.

2 Nov 2011

Scientists identify distinct tobacco transporter for nicotine metabolism

A team of Virginia Tech and Purdue University scientists have identified a distinct transporter used by tobacco plant cells for nicotine metabolism. The research appears in the Oct. 17 online before print issue of the Proceedings of the National Academy of Sciences (PNAS) in the article, "A tobacco nicotine uptake permease effects alkaloid metabolism."

2 Nov 2011

Glyphosine can prevent development of type 1 diabetes

Researchers at the University of Colorado School of Medicine have found a specific molecule that can prevent the development of type 1 diabetes in mice and has a similar effect on human cells from diabetic patients.

2 Nov 2011

Drinking cherry juice improves quality and duration of sleep

Drinking cherry juice significantly improves both the quality and duration of sleep, according to new findings from Northumbria University.

2 Nov 2011

Positive results from DARA's DB959 Phase 1b study on type 2 diabetes

DARA BioSciences, Inc., announces the positive results from a successfully completed Phase 1b clinical study for DB959, its peroxisome proliferator activated receptor (PPAR)-delta/gamma agonist, a non-TZD oral drug in development for the treatment of type 2 diabetes.

2 Nov 2011

Initiation of two IPI-145 Phase 1 clinical trials triggers $4M milestone payment to Intellikine

Intellikine, Inc., a company focused on the discovery and development of innovative, small molecule drugs targeting the PI3K/mTOR pathway, announced today that it has earned $4 million in milestone payments upon the initiation of two Phase 1 clinical trials of IPI-145.

31 Oct 2011

BerGenBio commences preclinical development of BGB324 anti-cancer drug

BerGenBio AS, an emerging oncology biopharma, today announced it has initiated preclinical development of its proprietary lead compound, BGB324. This compound will be a first-in-class inhibitor of AXL kinase.

31 Oct 2011

Python heart holds surprises that could be of use in cardiology

The expanding hearts of pythons have intrigued researchers. Leslie Leinwand - a University of Colorado at Boulder molecular biologist who studies heart disease in humans called pythons’ expanding hearts “amazing biology”. “They're not swelling up. They're building (heart) muscle,” he said.

30 Oct 2011

Researcher's compound disables bacteria instead of killing them

After 70 years, antibiotics are still the primary treatment for halting the spread of bacterial infections. But the prevalence of antibiotic resistance is now outpacing the rate of new drug discovery and approval. A microbiologist at the University of Wisconsin-Milwaukee (UWM) has discovered a different approach: Instead of killing the bacteria, why not disarm them, quashing disease without the worry of antibiotic resistance?

29 Oct 2011

Researchers identify compound that inhibits viral replication

Broad-spectrum antibiotics, which are active against a whole range of bacterial pathogens, have been on the market for a long time. Comparably versatile drugs to treat viral diseases, on the other hand, have remained elusive. Using a new approach, research teams led by Dr. Albrecht von Brunn of LMU Munich and Professor Christian Drosten from the University of Bonn have identified a compound that inhibits the replication of several different viruses, including the highly aggressive SARS virus that is responsible for severe acute respiratory syndrome.

29 Oct 2011

Scientists identify nicotinamidase enzyme as new drug target for Leishmaniasis

IRD scientist and their research partners recently identified the key role of nicotinamidase, an enzyme in the parasite Leishmania, essential for its survival but which does not exist in humans. The pathogen is incapable of developing in mammals In the absence of this enzyme. Specific targeting of this enzyme could lead to more effective ways of controlling this neglected tropical disease.

29 Oct 2011

Free computer application accurately models human motion

There are 640 muscles in the human body, or maybe it is 639. Or maybe it is 850. Or 656. It all depends on whom you ask. In any case, it is a lot. Stanford bioengineer Scott Delp knows; he has programmed almost every one into his latest work, OpenSim, a software application that helps medical professionals and bioengineers study, diagnose and correct abnormalities in how people move.

29 Oct 2011

Biogen Idec third quarter revenues increase 11% to $1.3 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its third quarter 2011 results.

28 Oct 2011

Biogen Idec enters global collaboration for oral Syk inhibitor program with Portola

Biogen Idec and Portola Pharmaceuticals, Inc. today announced that they have entered into an exclusive, worldwide collaboration and license agreement under which both companies will develop and commercialize highly selective, novel oral Syk inhibitors for the treatment of various autoimmune and inflammatory diseases, including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).

28 Oct 2011

Sulodexide drug fails to benefit diabetes patients with kidney disease

What was hoped to be a promising new drug to protect the kidneys has failed to benefit diabetes patients with kidney disease, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.

28 Oct 2011